Xian Zheng | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Dr. Xian Zheng | Pharmaceutical Science | Best Researcher Award

Assistant research Fellow of Affiliated Kunshan Hospital of Jiangsu University, China.

Xian Zheng is a prominent researcher specializing in Chinese herbal drugs, natural products, and nonalcoholic fatty liver disease (NAFLD). With a Ph.D. in Chinese pharmacy from China Pharmaceutical University, he currently serves as an Assistant Researcher at the Affiliated Kunshan Hospital of Jiangsu University and a part-time postdoctoral researcher at the Suzhou Institute of Nano-tech and Nano-bionics. Zheng leads several high-impact projects, including studies on arjunolic acid and liposome-based therapies for NAFLD, supported by major funding bodies like the National Natural Science Foundation of China. His research is well-regarded, with numerous publications in leading journals such as Phytomedicine and J Functional Foods. Zheng has been honored with awards like Jiangsu Double Innovation Doctor and Gusu Health Talents Plan-“Class D special talents”. His work showcases significant contributions to the field, marked by a strong publication record and leadership in innovative research.

Profile
Education

Xian Zheng’s educational background reflects a strong foundation in pharmacology and pharmacy. He earned his Ph.D. in Chinese Pharmacy from the College of Traditional Chinese Medicine at China Pharmaceutical University, Nanjing, in December 2021, under the supervision of Professor Zhiqi Yin. Prior to this, he completed his Master of Science in Pharmacology at the School of Pharmacy, Xuzhou Medical University, in June 2018, guided by Professor Yi Liu. Zheng’s academic journey began with a Ph.D. in Pharmacy from the School of Pharmacy, Nanjing2 University of Chinese Medicine, which he completed in June 2015. This extensive education, encompassing both traditional Chinese medicine and modern pharmacology, has provided him with a robust understanding of drug development and therapeutic applications, particularly in the realm of natural products and their effects on nonalcoholic fatty liver disease.

Professional Experience

Xian Zheng currently serves as an Assistant Researcher at the Department of Pharmacy, Affiliated Kunshan Hospital of Jiangsu University, where he has been contributing to cutting-edge research since February 2022. Additionally, he is a part-time postdoctoral researcher at the Suzhou Institute of Nano-tech and Nano-bionics, a position he has held since October 2022. Zheng’s professional journey includes significant achievements in studying Chinese herbal drugs and natural products, particularly in the context of nonalcoholic fatty liver disease (NAFLD). He leads multiple high-profile research projects funded by prestigious organizations such as the National Natural Science Foundation of China and the Gusu Health Talent Research Project. His expertise in pharmacology and his leadership in these research initiatives highlight his dedication and impact in advancing therapeutic strategies for NAFLD and related conditions.

Research Interest

Xian Zheng’s research interests primarily focus on Chinese herbal drugs and natural products, with a particular emphasis on their therapeutic potential for nonalcoholic fatty liver disease (NAFLD). His work explores innovative treatment approaches, such as the dual NAMPT activation theory, and the development of liposome-based drug delivery systems to enhance the efficacy of herbal compounds. Zheng’s research aims to uncover the underlying mechanisms of these treatments, such as their effects on metabolic pathways and cellular functions. He is dedicated to advancing the understanding of how traditional herbal remedies can be optimized and integrated into modern therapeutic strategies for complex liver diseases. By combining traditional pharmacological insights with contemporary biomedical techniques, Zheng seeks to bridge the gap between ancient remedies and modern medicine, ultimately improving clinical outcomes for patients with NAFLD and contributing to the broader field of natural product research.

Research Skills

Xian Zheng demonstrates exceptional research skills, particularly in the domain of pharmacology and natural product research. His expertise encompasses a comprehensive understanding of Chinese herbal drugs and their therapeutic applications, with a specific focus on nonalcoholic fatty liver disease (NAFLD). Zheng excels in designing and leading innovative research projects, such as exploring dual NAMPT activation and developing liposome-based therapies for NAFLD. His ability to secure funding from prestigious organizations, including the National Natural Science Foundation of China, underscores his proficiency in research proposal development and project management. Zhengā€™s analytical skills are evident in his extensive publication record in reputable journals, where he contributes to advancing knowledge in his field. His role as a part-time postdoctoral researcher further reflects his commitment to scientific inquiry and collaboration. Overall, Zheng’s research skills are marked by a blend of innovative thinking, effective project leadership, and a strong publication track record.

Awards and Recognition

Xian Zheng has earned notable recognition in his field through a series of prestigious awards and honors. His achievements include being named a Jiangsu Double Innovation Doctor, which acknowledges his exceptional contributions to innovative research in Chinese pharmacy. Additionally, Zheng is distinguished as a ā€œClass D special talentsā€ under the Gusu Health Talents Plan, underscoring his impactful work in the realm of natural products and nonalcoholic fatty liver disease. He was also recognized as a Kunshan Youth Post Expert in 2022 and a Suzhou Youth Post Expert in 2023, highlighting his significant contributions to the scientific community and his leadership in advancing research. These accolades reflect Zhengā€™s dedication and impact in the field of pharmacology and his commitment to advancing therapeutic approaches through his innovative research efforts.

Conclusion

Dr. Tao Song is a strong candidate for the Best Researcher Award due to his significant contributions to the field of catalysis and green chemistry. His innovative research and high-impact publications demonstrate a clear potential for future leadership in the field. To further strengthen his candidacy, Dr. Song could focus on expanding the impact of his research through interdisciplinary collaborations and leadership roles. Given his achievements and potential, Dr. Song is well-suited for recognition as a leading researcher in his field.

Publications Top Notes

  1. Arjunolic Acid from Cyclocarya paliurus Selectively Inhibits Glucagon Secretion from Ī± Cells and Ameliorates Diabetes via Ephrin-A1 and EphA4 Interaction
    • Authors: Fang, C.-Q., Teng, Y., Wang, Y.-T., Cao, X.-L., Jiang, C.-H.
    • Year: 2022
  2. Aloin A Prevents Ulcerative Colitis in Mice by Enhancing the Intestinal Barrier Function via Suppressing the Notch Signaling Pathway
    • Authors: Jiang, H., Shi, G.-F., Fang, Y.-X., Zhang, J., Yin, Z.-Q.
    • Year: 2022
    • Citations: 11
  3. Protective Effects of Cyclocarya paliurus on Hyperuricemia and Urate-Induced Inflammation
    • Authors: Zhu, L.-H., Xu, Y.-Y., Zhu, L.-P., Zhang, J., Yin, Z.-Q.
    • Year: 2022
    • Citations: 9
  4. Cyclocarya paliurus Triterpenoids Attenuate Glomerular Endothelial Injury in Diabetic Rats via ROCK Pathway
    • Authors: Yang, R., Xu, S., Zhang, X., Yin, Z., Pan, K.
    • Year: 2022
    • Citations: 8
  5. Chrysin Inhibits Hepatocellular Carcinoma Progression Through Suppressing Programmed Death Ligand 1 Expression
    • Authors: Rong, W., Wan, N., Zheng, X., Gao, Z.-J., Zhang, J.
    • Year: 2022
    • Citations: 17
  6. New Dammarane-Type Triterpenoid Saponins from Gynostemma pentaphyllum and Their Sirt1 Agonist Activity
    • Authors: Lou, Y.-Y., Zheng, X., Huang, Y.-P., Yin, Z.-Q., Pan, K.
    • Year: 2021
    • Citations: 12
  7. Arjunolic Acid from Cyclocarya paliurus Ameliorates Nonalcoholic Fatty Liver Disease in Mice via Activating Sirt1/AMPK, Triggering Autophagy and Improving Gut Barrier Function
    • Authors: Zheng, X., Zhang, X.-G., Liu, Y., Zhang, J., Yin, Z.-Q.
    • Year: 2021
    • Citations: 6
  8. Aloe Vera Mitigates Dextran Sulfate Sodium-Induced Rat Ulcerative Colitis by Potentiating Colon Mucus Barrier
    • Authors: Shi, G., Jiang, H., Feng, J., Jiang, C., Zhang, J.
    • Year: 2021
    • Citations: 30
  9. Four New Dammarane Triterpenoid Glycosides from the Leaves of Cyclocarya paliurus and Their SIRT1 Activation Activities
    • Authors: Zhu, L.-P., Yang, H.-M., Zheng, X., Zhang, J., Yin, Z.-Q.
    • Year: 2021
    • Citations: 7
  10. Gypenoside LVI Improves Hepatic LDL Uptake by Decreasing PCSK9 and Upregulating LDLR Expression
    • Authors: Wang, J., Wang, Y.-S., Huang, Y.-P., Yin, Z.-Q., Zhang, J.
    • Year: 2021
    • Citations: 21